Budesonide/formoterol - Pearl Therapeutics

Drug Profile

Budesonide/formoterol - Pearl Therapeutics

Alternative Names: Budesonide and formoterol (BFF MDI) - Pearl Therapeutics; Formoterol/budesonide - Pearl Therapeutics; PT-009

Latest Information Update: 04 Jan 2017

Price : $50

At a glance

  • Originator Pearl Therapeutics
  • Class Antiasthmatics; Bronchodilators; Ethanolamines; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Chronic obstructive pulmonary disease

Most Recent Events

  • 20 Mar 2017 Pearl Therapeutics plans a phase III trial for Chronic obstructive pulmonary disease (Combination therapy) (NCT03081247)
  • 03 Sep 2016 Efficacy data from a phase IIb trial in Chronic obstructive pulmonary disease presented at the 26th Annual Congress of the European Respiratory Society
  • 01 Apr 2016 Pearl Therapeutics initiates the phase III Sophos trial for Chronic obstructive pulmonary disease in USA (Inhalation) (NCT02727660)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top